Antidepressant Drug
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 1440
Special Issue Editor
Special Issue Information
Dear Colleagues,
Depression disorder is a common heterogeneous mental disorder that affects all aspects of life of patients as well as people around them. Depression affects 3.8% of the population, including children and the elderly. Moreover, 10-30% of treated patients remain significantly symptomatic and resistant to conventional treatments, despite receiving antidepressant treatment and switching from first-line antidepressant drugs to phase 2 trials [1].
The treatment of depression raises difficulties not only for clinicians but also patients. Antidepressants (Ads) mostly work by increasing extrasynaptic monoamine levels in the brain, which leads to many side effects on the peripheral nervous system. Moreover, ADs have a delayed onset of action even after weeks of treatment. Therefore, new rapid-action antidepressants, among them ketamine and NMDA antagonists, are being intensively studied. Nowadays, antidepressant drugs are divided into five classes: SSRIs, SNRIs, TCAs, MAOIs and atypical antidepressants with unique mechanisms of action. Furthermore, natural antidepressants such as omega-3-fatty acids or exercise, which can supplement antidepressant therapy, are gaining traction [2]. Therefore, the development of new drugs and methods for depression treatment is critical.
In this Special Issue, we aim to present well-known and new therapeutic agents and strategy for depression treatment. We will be focusing on traditional treatments and novel antidepressant molecules, such as peptides or cannabinoids, as well nutrition supplementation, which can be important for MDD treatment. In this Special Issue, we want to expand the knowledge on antidepressant drugs and their mechanism of action.
- https://www.who.int/news-room/fact-sheets/detail/depression
- Rantamäki T, Yalcin I. Antidepressant drug action--From rapid changes on network function to network rewiring. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:285-92. doi: 10.1016/j.pnpbp.2015.06.001. Epub 2015 Jun 9. PMID: 26066070.
Dr. Paulina Misztak
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antidepressant
- molecular mechanism of drugs
- new targets for depression treatment
- depression
- MDD
- animal models of depression
- nutrition in depression
- small molecules
